1-3 of 3
Alan L. Landay
Close
Sort by
Journal Articles

The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial

Clinical Trials & Observations
Peter W. Hunt, Nancy S. Shulman, Timothy L. Hayes, Viktor Dahl, Ma Somsouk, Nicholas T. Funderburg, Bridget McLaughlin, Alan L. Landay, Oluwatoyin Adeyemi, Lee E. Gilman, Brian Clagett, Benigno Rodriguez, Jeffrey N. Martin, Timothy W. Schacker, Barbara L. Shacklett, Sarah Palmer, Michael M. Lederman, Steven G. Deeks
Journal: Blood
Blood (2013) 121 (23): 4635–4646.
https://doi.org/10.1182/blood-2012-06-436345
Published: 2013
Includes: Supplemental data
Journal Articles

IL-7 administration drives T cell–cycle entry and expansion in HIV-1 infection

Clinical Trials & Observations
Irini Sereti, Richard M. Dunham, John Spritzler, Evgenia Aga, Michael A. Proschan, Kathy Medvik, Catherine A. Battaglia, Alan L. Landay, Savita Pahwa, Margaret A. Fischl, David M. Asmuth, Allan R. Tenorio, John D. Altman, Lawrence Fox, Susan Moir, Angela Malaspina, Michel Morre, Renaud Buffet, Guido Silvestri, Michael M. Lederman
Journal: Blood
Blood (2009) 113 (25): 6304–6314.
https://doi.org/10.1182/blood-2008-10-186601
Published: 2009
Includes: Supplemental data
Journal Articles

CD8 + T cells that express CD4 on their surface (CD4 dim CD8 bright T cells) recognize an antigen-specific target, are detected in vivo, and can be productively infected by T-tropic HIV

Andrew Zloza, Yvonne B. Sullivan, Elizabeth Connick, Alan L. Landay, Lena Al-Harthi
Journal: Blood
Blood (2003) 102 (6): 2156–2164.
https://doi.org/10.1182/blood-2002-07-1972
Published: 2003